Approved by Macau Health Bureau in 2001
Latropine 0.05%
Innovative solution for childhood myopia prevention and control
Clinically proven low-concentration atropine eye drops designed for children aged 4-12
Research by The Chinese University of Hong Kong confirms 46.4% reduction in myopia incidence
Quality manufactured by Taiwan Wu Fu Chemical & Pharmaceutical Co., Ltd.
World's First Research from CUHK
Proves That Low-Concentration Atropine Can Prevent Childhood Myopia
LAMP2 Clinical Trial Results Comparison
| 0.05% Atropine Group | 0.01% Atropine Group | Placebo Group | |
|---|---|---|---|
| 2-Year Cumulative Myopia Incidence | 28.4% | 45.9% | 53.0% |
| Fast Myopia Progression in 2 Years | 25.0% | 45.1% | 53.9% |
| Photophobia Adverse Events Reported | 12.9% | 18.9% | 12.2% |
* 474 non-myopic children aged 4-9 years participated, study period 2017-2020
46.4%
Relative reduction in myopia incidence
474
Children aged 4-9 participated in study
2 Years
Clinical trial period
Company Information
Exclusive Distributor
WUZHOU DRUG INTERNATIONAL TRADING LIMITED
澳門五洲藥物國際貿易有限公司
Travessa da Central Térmica no22 Edifício Hantec r/c "AJ", Macau
+853 6588 5387
info@droga.cn
Manufacturer
Taiwan Wu Fu Chemical & Pharmaceutical Co., Ltd.
台灣五福化學製藥股份有限公司
Professional pharmaceutical manufacturing with quality assurance
Product Gallery
Product Package
Professional Product Display
Product Inventory
Product Details
Product Information
Clinical Research Data